Fujifilm Unveils Japan's Largest Bio CDMO Facility: A Comprehensive Drug Development Partner
Fujifilm Group, a leader in healthcare innovation, is celebrating a significant milestone in its commitment to advancing global healthcare. The company has recently completed one of Japan's largest Contract Development and Manufacturing Organization (CDMO) facilities in Toyama Prefecture, further solidifying its position as a trusted partner in the pharmaceutical and biotechnology industries.
A Comprehensive Drug Development Partner
Fujifilm offers a comprehensive suite of drug discovery support solutions, including cell culture media, reagents, and induced pluripotent stem (iPS) cells, alongside its CDMO services. This holistic approach enables the company to provide end-to-end support to a diverse range of customers, from early-stage drug development to commercial production. With a focus on being 'Partners for Life,' Fujifilm is dedicated to advancing healthcare and delivering innovative therapies to patients worldwide.
Single-Use Components: Enhancing Efficiency and Flexibility
One of the key innovations in Fujifilm's CDMO services is the utilization of single-use components in biopharmaceutical manufacturing processes. These components, compared to traditional stainless-steel systems, eliminate the need for cleaning and sterilization, enhancing flexibility and efficiency. This has led to their widespread adoption in recent years, revolutionizing the manufacturing process.
Targeted Drug Delivery: Antibody-Drug Conjugates (ADCs)
Fujifilm's expertise also extends to the development of targeted drug delivery systems, such as Antibody-Drug Conjugates (ADCs). ADCs combine an antibody with a drug, like an anticancer agent, allowing for the targeted delivery of the drug to cancer cells. This approach offers high therapeutic efficacy while minimizing side effects, making it a valuable tool in cancer treatment.
Japan's Biopharmaceutical Trade Deficit
Interestingly, despite Japan's advancements in biopharmaceuticals, the country recorded a trade deficit of JPY1.7 trillion in 2024, according to trade statistics from the Ministry of Finance (Export Statistical Item Classification No. 30.02). This highlights the ongoing challenges and opportunities in the global biopharmaceutical market.
Fujifilm's Global Investment in Bio CDMO Business
Since 2011, Fujifilm has invested over JPY1 trillion in its bio CDMO business, establishing itself as a global leader in comprehensive biopharmaceutical services. FUJIFILM Biotechnologies, the core company of this business, leverages its extensive experience and proprietary high-productivity technologies, operating sites in the UK, U.S., and Denmark. The kojoX™ global network, with its modular facilities and standardized processes, enables rapid technology transfer and flexible supply chain support.
Expanding Capacity for Antibody Drug Demand
To meet the growing demand for antibody drugs, Fujifilm is strategically expanding its production capacity at its North Carolina and Denmark sites. By 2028, the company aims to secure a total production capacity of over 750,000 liters, solidifying its position as a leading provider of antibody drug manufacturing services.
